Knockout Tested Rabbit Recombinant Monoclonal TLR9 antibody. Suitable for WB, IHC-P and reacts with Human samples.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
WB | IHC-P | Flow Cyt (Intra) | ICC/IF | |
---|---|---|---|---|
Human | Tested | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (PubMed:14716310). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:11564765, PubMed:17932028). Controls lymphocyte response to Helicobacter infection (By similarity). Upon CpG stimulation, induces B-cell proliferation, activation, survival and antibody production (PubMed:23857366).
UNQ5798/PRO19605, TLR9, UNQ5798/PRO19605, Toll-like receptor 9
Knockout Tested Rabbit Recombinant Monoclonal TLR9 antibody. Suitable for WB, IHC-P and reacts with Human samples.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR14964-2
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and dilution buffer: 5% NFDM/TBST
All lanes: Western blot - Anti-TLR9 antibody [EPR14964-2] (ab187148) at 1/5000 dilution
Lane 1: Daudi cell lysate at 10 µg
Lane 2: Raji cell lysate at 10 µg
Lane 3: Ramos cell lysate at 10 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 115 kDa
False colour image of Western blot: Anti-TLR9 antibody [EPR14964-2] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab187148 was shown to bind specifically to TLR9. A band was observed at 140 kDa in wild-type Raji cell lysates with no signal observed at this size in TLR9 knockout cell line ab280879 (knockout cell lysate ab282939). To generate this image, wild-type and TLR9 knockout Raji cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes: Western blot - Anti-TLR9 antibody [EPR14964-2] (ab187148) at 1/1000 dilution
Lane 1: Wild-type Raji cell lysate at 20 µg
Lane 2: TLR9 knockout Raji cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 115 kDa
Observed band size: 140 kDa
Immunohistochemistry analysis of paraffin-embedded Human breast carcinoma tissue sections labelling TLR9 with ab187148 at 1/1000 dilution. The section was incubated with ab187148 for 30 mins at room temperature. Ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used as the secondary antibody. Sections were counterstained with Hematoxylin. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.
Positive staining on some immune stroma cells in human breast carcinoma tissue. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.
Immunohistochemistry analysis of paraffin-embedded Human tonsil tissue sections labelling TLR9 with ab187148 at 1/1000 dilution. The section was incubated with ab187148 for 30 mins at room temperature. Ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used as the secondary antibody. Sections were counterstained with Hematoxylin. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.
Positive staining on some immune cells in human tonsil tissue. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com